Xencor Inc
F:XE9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
X
|
Xencor Inc
F:XE9
|
US |
|
H
|
Hangzhou Fortune Gas Cryogenic Group Co Ltd
SSE:603173
|
CN |
|
Writeup Co Ltd
TSE:6580
|
JP |
|
Hopson Development Holdings Ltd
HKEX:754
|
HK |
|
A
|
Arise AB
STO:ARISE
|
SE |
|
I
|
Indag Rubber Ltd
BSE:509162
|
IN |
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
US |
|
P
|
Prodigy PCL
SET:PDG
|
TH |
|
Payoneer Global Inc
NASDAQ:PAYO
|
US |
|
Anhui Zhongding Sealing Parts Co Ltd
SZSE:000887
|
CN |
|
T
|
Tokmanni Group Corp
LSE:0RG2
|
FI |
|
Nihon Jyoho Create Co Ltd
TSE:4054
|
JP |
Xencor Inc
Xencor Inc. is an innovative biotechnology company, distinguished by its commitment to harnessing the power of engineered monoclonal antibodies to fight complex diseases, especially within the realms of cancer and autoimmune disorders. Founded in 1997 and headquartered in Monrovia, California, Xencor relies on its proprietary XmAb technology platform – a sophisticated approach that enhances the structure and function of monoclonal antibodies to improve therapeutic performance. This technology enables Xencor to develop antibodies that are more potent, stable, and precise, ultimately driving their efficacy in targeting particular cellular mechanisms associated with disease progression while minimizing side effects. By focusing on core biological processes, Xencor leverages its platform to innovate new therapies that offer significant improvements over existing treatments, making it a nimble player in the competitive biotech landscape.
Xencor's business model hinges on a dual strategy of internal drug development and strategic collaborations. Internally, Xencor is advancing a robust pipeline of drug candidates aimed at addressing various unmet medical needs, many of which are in various stages of clinical trials. These in-house projects are crucial for establishing the company's reputation as a leader in antibody engineering. In parallel, Xencor partners with larger pharmaceutical companies, licensing its XmAb technology and co-developing drugs—a model that provides a steady revenue stream from milestone payments, royalties, and research support. This hybrid approach not only diversifies Xencor's risk portfolio but also enhances its financial resilience, enabling a sustainable path to growth amidst the volatile biotech sector. Through this innovative framework, Xencor is poised to continue its influence in the biopharmaceutical industry, driven by a mission to bring transformative therapies to patients in need.
Xencor Inc. is an innovative biotechnology company, distinguished by its commitment to harnessing the power of engineered monoclonal antibodies to fight complex diseases, especially within the realms of cancer and autoimmune disorders. Founded in 1997 and headquartered in Monrovia, California, Xencor relies on its proprietary XmAb technology platform – a sophisticated approach that enhances the structure and function of monoclonal antibodies to improve therapeutic performance. This technology enables Xencor to develop antibodies that are more potent, stable, and precise, ultimately driving their efficacy in targeting particular cellular mechanisms associated with disease progression while minimizing side effects. By focusing on core biological processes, Xencor leverages its platform to innovate new therapies that offer significant improvements over existing treatments, making it a nimble player in the competitive biotech landscape.
Xencor's business model hinges on a dual strategy of internal drug development and strategic collaborations. Internally, Xencor is advancing a robust pipeline of drug candidates aimed at addressing various unmet medical needs, many of which are in various stages of clinical trials. These in-house projects are crucial for establishing the company's reputation as a leader in antibody engineering. In parallel, Xencor partners with larger pharmaceutical companies, licensing its XmAb technology and co-developing drugs—a model that provides a steady revenue stream from milestone payments, royalties, and research support. This hybrid approach not only diversifies Xencor's risk portfolio but also enhances its financial resilience, enabling a sustainable path to growth amidst the volatile biotech sector. Through this innovative framework, Xencor is poised to continue its influence in the biopharmaceutical industry, driven by a mission to bring transformative therapies to patients in need.
Pipeline Focus: Xencor is shifting its resources to prioritize T-cell engagers, especially bispecific antibodies for solid tumors, while reducing investment in cytokine drug candidates.
Vudalimab Results: Vudalimab showed encouraging single-agent activity in heavily pre-treated metastatic castration-resistant prostate cancer, with a RECIST response rate of 35% and disease control rate of 50%.
Safety Profile: Vudalimab's safety is consistent with other checkpoint inhibitors, though one Grade 5 immune-related hepatitis case was reported among over 240 treated patients.
Financial Strength: The company ended 2023 with $697 million in cash, expecting its runway to extend into 2027.
Clinical Progress: Multiple Phase I dose-escalation studies are ongoing for new T-cell engagers, and the first frontline lung cancer study for vudalimab has started dosing patients.
Guidance: Xencor expects to enroll 20–30 patients in vudalimab monotherapy and combination cohorts by the first half of next year to inform go/no-go decisions.
